Submit Content Become a member

Visioneering Technologies (ASX: VTI) has obtained positive preliminary year two data from the ongoing PROTECT (PROgressive Myopia Treatment Evaluation for NaturalVue Multifocal Contact Lens Trial) study.

The preliminary two-year data highlight the safety and efficacy of NaturalVue Multifocal 1 Day Contact Lenses in managing myopia progression in children. The results demonstrate a significant reduction in refractive error and axial length growth compared to the control group. The two-year adjusted treatment effect in refractive error progression was 0.60 D (diopters), representing a 53% reduction compared to the control group.

he two-year adjusted treatment effect in axial length elongation was 0.25 mm, indicating an 86% retardation relative to the control group. Both two-year adjusted treatment effect values are consistent with the two-year values achieved by the only FDA-approved therapy for myopia progression control in a separate study

Combined with previously published six-year retrospective (real-world) data in Clinical Ophthalmology (2022) and independent studies released in September 2023, these findings affirm NaturalVue Multifocal’s effectiveness in controlling myopia progression in children.

VTI remains committed to analysing and sharing additional details as the study progresses. This announcement of the preliminary two-year data follows the release of the interim one-year data the full 1-year results.

Looking Ahead

VTI expects to release more detailed two-year data and the three-year data when available. These findings, combined with earlier data from independent studies, support NaturalVue Multifocal’s effectiveness in controlling myopia progression across diverse patient populations thus far.

About PROTECT

‘PROTECT’ (PROgressive Myopia Treatment Evaluation for NaturalVue Multifocal Contact Lens Trial) is a three-year, prospective, double-masked multi-national trial evaluating the safety and effectiveness of NaturalVue Multifocal Contact Lenses for slowing myopia progression (participating investigators in the United States, Canada, Hong Kong, and Singapore) involving 145 kids.

Rate article from Colin Hay: